At Vir Biotechnology, Inc., we leverage the immense potential of the immune system to transform lives by discovering and developing medicines for serious infectious diseases and cancer. We focus on the therapeutic areas in which we believe we can most benefit patients. Our foundational efforts in chronic hepatitis delta are complemented by strategic programs in oncology. Every day, we work with the utmost urgency to deliver potentially transformative medicines for patients. Our pipeline is built on two technology platforms which enable us to rapidly identify, optimize and advance candidates from concepts to the clinic: our next-generation antibody platform and our protease-releasable masking platform in infectious disease and cancer. Explore our full pipeline here: https://bit.ly/3tr7FPm It has come to our attention that there have been various recruitment scams targeting job seekers on LinkedIn. Vir Biotechnology, Inc. is committed to your privacy and will never request sensitive personal information including banking details through email, text message, social media or video software platforms. We also will never request a financial commitment from a candidate as part of the application process. Learn more about Vir Bio's recruiting process: https://bit.ly/461EgJN
Looking for a particular Vir Biotechnology, Inc. employee's phone or email?
The Vir Biotechnology, Inc. annual revenue was $63.7 million in 2026.
Marianne de Backer is the CEO and President of Vir Biotechnology, Inc..
455 people are employed at Vir Biotechnology, Inc..
Vir Biotechnology, Inc. is based in San Francisco, California.
The NAICS codes for Vir Biotechnology, Inc. are [325413, 325414, 3254, 32541, 325, 32].
The SIC codes for Vir Biotechnology, Inc. are [283, 28].